Virginia A Espina

age ~65

from Rockville, MD

Also known as:
  • Virginia Anne Espina
  • Virginia H Espina
  • Virginia A Espana
Phone and address:
4917 Bel Pre Rd, Rockville, MD 20853
3014605417

Virginia Espina Phones & Addresses

  • 4917 Bel Pre Rd, Rockville, MD 20853 • 3014605417
  • Bethesda, MD
  • Morgantown, WV
  • 4917 Bel Pre Rd, Rockville, MD 20853

Work

  • Company:
    National institutes of health
    May 2002 to May 2005
  • Position:
    Manager, laser capture microdissection core facility

Education

  • Degree:
    Doctorates, Doctor of Philosophy
  • School / High School:
    George Mason University
    2010 to 2013
  • Specialities:
    Philosophy

Skills

Proteomics • Immunohistochemistry • Clinical Research • Western Blotting • Animal Models • Clinical Trials • Genetics • Mammalian Cell Culture • Science • Cell Culture • Hematology • Life Sciences • Molecular Biology • Statistics • Qpcr • Elisa • Biochemistry • Laboratory • Laser Capture Microdissection • Clia • Reverse Phase Protein Microarray • Urinalysis • Biotechnology • Cell Biology • Genomics • Microbiology • Protein Chemistry • Research • Clinical Laboratory Management • Qualitative Research • Clinical Chemistry • Blood Bank

Languages

English

Ranks

  • Certificate:
    Medical Technologist (Ascp)

Emails

Industries

Higher Education

Us Patents

  • Smart Hydrogel Particles For Biomarker Harvesting

    view source
  • US Patent:
    8497137, Jul 30, 2013
  • Filed:
    Aug 19, 2008
  • Appl. No.:
    12/194360
  • Inventors:
    Alessandra Luchini - Fairfax VA, US
    Lance Liotta - Bethesda MD, US
    Emanuel Petricoin - Gainesville VA, US
    Barney Bishop - Annandale VA, US
    Caterina Longo - Fairfax VA, US
    Virginia Espina - Rockville MD, US
    Alexis Patanarut - Burke VA, US
  • International Classification:
    G01N 33/545
  • US Classification:
    436531, 42840224, 428407, 435 61, 436534, 436535
  • Abstract:
    Capture particles for harvesting analytes from solution and methods for using them are described. The capture particles are made up of a polymeric matrix having pore size that allows for the analytes to enter the capture particles. The pore size of the capture particles are changeable upon application of a stimulus to the particles, allowing the pore size of the particles to be changed so that analytes of interest remain sequestered inside the particles. The polymeric matrix of the capture particles are made of co-polymeric materials having a structural monomer and an affinity monomer, the affinity monomer having properties that attract the analyte to the capture particle. The capture particles may be used to isolate and identify analytes present in a mixture. They may also be used to protect analytes which are typically subject to degradation upon harvesting and to concentrate low an analyte in low abundance in a fluid.
  • Mtor Pathway Theranostic

    view source
  • US Patent:
    8628931, Jan 14, 2014
  • Filed:
    Oct 18, 2006
  • Appl. No.:
    12/083866
  • Inventors:
    Lance A. Liotta - Rockville MD, US
    Virginia Espina - Rockville MD, US
  • Assignee:
    George Mason Intellectual Properties, Inc. - Fairfax VA
  • International Classification:
    G01N 33/53
    G01N 33/50
    G01N 33/52
  • US Classification:
    435 723, 435 71, 435 72, 435 721, 435 4051, 435 4052, 435967, 435973, 436501, 436503, 436 63, 436 64
  • Abstract:
    This invention relates, e. g. , to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e. g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway.
  • Ocular Fluid Markers

    view source
  • US Patent:
    20070224644, Sep 27, 2007
  • Filed:
    Jan 29, 2007
  • Appl. No.:
    11/698998
  • Inventors:
    Lance Liotta - Bethesda MD, US
    Weidong Zhou - Manassas VA, US
    Virginia Espina - Rockville MD, US
    Emanuel Petricoin - Gainesville VA, US
  • International Classification:
    G01N 33/53
    C12Q 1/48
    G06F 19/00
    A61M 31/00
  • US Classification:
    435007100, 435015000, 604500000, 702019000
  • Abstract:
    The present invention relates to the analysis and monitoring of ocular fluids for determining the physiological state of an organism, to monitor drug efficacy and dynamics, for early disease detection, as well as to certain molecular markers and fingerprints of identified molecules or molecule fragments in such analysis.
  • Inhibition Of Brain Enzymes Involved In Cerebral Amyloid Angiopathy And Macular Degeneration

    view source
  • US Patent:
    20090018094, Jan 15, 2009
  • Filed:
    Nov 30, 2007
  • Appl. No.:
    11/948856
  • Inventors:
    Wolff Kirsch - Redlands CA, US
    Lance A. Liotta - Bethesda MD, US
    William Van Nostrand - East Setauket NY, US
    Harry V. Vinters - Venice CA, US
    Virginia A. Espina - Rockville MD, US
  • Assignee:
    LOMA LINDA UNIVERSITY MEDICAL CENTER - Loma Linda CA
    GEORGE MASON UNIVERSITY - Arlington VA
    STONY BROOK UNIVERSITY - Stony Brook CA
    THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Los Angeles CA
  • International Classification:
    A61K 31/7105
    A61P 25/28
  • US Classification:
    514 44
  • Abstract:
    A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient.
  • Inhibition Of Brain Enzymes Involved In Cerebral Amyloid Angiopathy And Macular Degeneration

    view source
  • US Patent:
    20100047336, Feb 25, 2010
  • Filed:
    Aug 17, 2009
  • Appl. No.:
    12/542635
  • Inventors:
    Wolff Kirsch - Redlands CA, US
    Lance A. Liotta - Bethesda MD, US
    William Van Nostrand - East Setauket NY, US
    Harry V. Vinters - Venice CA, US
    Virginia A. Espina - Rockville MD, US
  • Assignee:
    LOMA LINDA UNIVERSITY MEDICAL CENTER - Loma Linda CA
    GEORGE MASON UNIVERSITY - Arlington VA
    STONY BROOK UNIVERSITY - Stony Brook CA
    THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Los Angeles CA
  • International Classification:
    A61K 9/127
    A61K 31/7052
    A61K 31/555
    A61P 25/28
  • US Classification:
    424450, 514 44 A, 514185
  • Abstract:
    A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient.
  • Tissue Preservation And Fixation Method

    view source
  • US Patent:
    20100068690, Mar 18, 2010
  • Filed:
    Oct 26, 2007
  • Appl. No.:
    12/447773
  • Inventors:
    Lance A. Liotta - Bethesda MD, US
    David Geho - Oakton VA, US
    Virginia A. Espina - Rockville MD, US
  • Assignee:
    George Mason Intellectual Properties, Inc. - Fairfax VA
  • International Classification:
    A01N 1/02
    G01N 33/48
    C07K 14/00
    C12M 1/00
  • US Classification:
    435 11, 435 405, 530402, 4352841
  • Abstract:
    This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises (1) a fixative that is effective to fix the phosphoproteins, and that has a sufficient water content to be soluble for a stabilizer and/or a permeability enhancing agent); (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; and (3) a permeability enhancing agent (e.g. PEG). Methods are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. the following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample.
  • Biomarkers For Neurological Conditions

    view source
  • US Patent:
    20100159486, Jun 24, 2010
  • Filed:
    Nov 1, 2007
  • Appl. No.:
    12/513032
  • Inventors:
    Lance A. Liotta - Bethesda MD, US
    Wolff Kirsch - Redlands CA, US
    Virginia Espina - Rockville MD, US
    Emanuel Petricoin, III - Gainesville VA, US
    Mark Ross - Charlottesville VA, US
    Claudius Mueller - Loma Linda CA, US
    Shino Magaki - Redlands CA, US
  • International Classification:
    G01N 33/53
    C12Q 1/02
    G01N 33/566
    G01N 33/00
    C07K 16/18
  • US Classification:
    435 792, 435 71, 435 29, 436501, 436 89, 5303873, 5303879
  • Abstract:
    Low molecular weight (LMW) peptides have been discovered that are indicative of neurological conditions, such as Alzheimer's Disease (AD), cognitive impairment and brain microhemmorhages. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting neurological conditions and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting neurological conditions during the early stages without invasive procedures.
  • Post-Exposure Prophylaxis And Treatment Of Infections

    view source
  • US Patent:
    20110046039, Feb 24, 2011
  • Filed:
    Mar 6, 2008
  • Appl. No.:
    12/530538
  • Inventors:
    Serguei G. Popov - Bristow VA, US
    Taissia Popov - Bristow VA, US
    Virginia Espina - Rockville MD, US
    Charles Bailey - Cross Junction VA, US
    Lance A. Liotta - Bethesda MD, US
    Emanuel Petricoin - Gainesville VA, US
  • Assignee:
    George Mason Intellectual Properties Inc. - Fairfax VA
  • International Classification:
    A61K 38/07
    A61P 31/04
  • US Classification:
    514 24
  • Abstract:
    The invention provides methods and materials for identifying agents for preventing and/or treating anthrax and similar diseases. Embodiments provide strains and model systems for studying non-lethal and lethal exposure to anthrax and similar disease vectors. Embodiments provide materials and methods for using the strains and model systems for differential profiling, such as proteomic profiling, such as differentiation phosphorylation profiling, to target identification and therapeutics discovery and development. Embodiments provide pharmaceutically acceptable compositions, and methods for using them to prevent and/or treat anthrax and similar diseases comprising an agent that decreases the activity of caspase , such as YVAD, and/or an agent that increases the phosphorylation of AKT, such as IB-MECA or Cl-IB-MECA, together with, in particular embodiments, an antibiotic, such as ciprofloxacin. Kits comprising the same are provided as well, among other things.

Resumes

Virginia Espina Photo 1

Research Professor

view source
Location:
Rockville, MD
Industry:
Higher Education
Work:
National Institutes of Health May 2002 - May 2005
Manager, Laser Capture Microdissection Core Facility

Shady Grove Adventist Hospital Feb 2002 - May 2002
Interim Lab Director

Adventist Health Care/Shady Grove Adventist Hospital Mar 1993 - Feb 2002
Medical Technologist

George Mason University Mar 1993 - Feb 2002
Research Professor
Education:
George Mason University 2010 - 2013
Doctorates, Doctor of Philosophy, Philosophy
The Johns Hopkins University 1997 - 1999
Master of Science, Masters, Biotechnology
Rochester Institute of Technology 1978 - 1982
Bachelors, Bachelor of Science
Skills:
Proteomics
Immunohistochemistry
Clinical Research
Western Blotting
Animal Models
Clinical Trials
Genetics
Mammalian Cell Culture
Science
Cell Culture
Hematology
Life Sciences
Molecular Biology
Statistics
Qpcr
Elisa
Biochemistry
Laboratory
Laser Capture Microdissection
Clia
Reverse Phase Protein Microarray
Urinalysis
Biotechnology
Cell Biology
Genomics
Microbiology
Protein Chemistry
Research
Clinical Laboratory Management
Qualitative Research
Clinical Chemistry
Blood Bank
Languages:
English
Certifications:
Medical Technologist (Ascp)
License 147578

Facebook

Virginia Espina Photo 2

Maria Virginia Espina Diaz

view source
Friends:
Ornella Paolina Mincone Gajardo, Venegas Daniel, Macarena Bravo Carrasco

Youtube

Preventing Breast Cancer Before It Starts by ...

Preventing Breast Cancer Before It Starts Virginia Espina, PhD, MT (AS...

  • Duration:
    12m 50s

Resume your Avon business Virginia Espina-Laboy

Virginia Espina-Laboy, Avon District 1108 Sales Manager inDade County,...

  • Duration:
    36s

Presentacin Notas de Papel Resaltado Collage ...

  • Duration:
    14m 11s

Retoma tu negocio de Avon Virginia Espina-Laboy

Virginia Espina-Laboy, Gerente del Distrito 1108 de Avon en el Condado...

  • Duration:
    40s

Virginia To Vegas - Selfish

Virginia To Vegas' new single Selfish is out now! Get it at Spotify: ...

  • Duration:
    3m 35s

Hydrogel Nanoparticle Harvesting-Plasm... De...

... Experimental Protocol Ruben Magni, Benjamin H. Espina, Lance A. Li...

  • Duration:
    2m 1s

Googleplus

Virginia Espina Photo 3

Virginia Espina

Virginia Espina Photo 4

Virginia Espina

Virginia Espina Photo 5

Virginia Espina

Tagline:
Independent,caring,friendly
Bragging Rights:
Single mother with 2 kids

Get Report for Virginia A Espina from Rockville, MD, age ~65
Control profile